Tiragolumab and TIGIT: pioneering the next era of cancer immunotherapy

Tiragolumab, a monoclonal antibody (mAb) targeting T cell immunoreceptor with Ig and ITIM domains (TIGIT), represents a novel approach in cancer immunotherapy. TIGIT, an immunological checkpoint receptor, suppresses T cell activation and promotes immune evasion in various cancers. By inhibiting TIGI...

Full description

Bibliographic Details

Published in:	Frontiers in Pharmacology
Main Author:	Kosar Ghasemi
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-06-01
Subjects:	tiragolumab TIGIT cancer immunotherapy immune checkpoint inhibitor 19 cancer
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1568664/full